Romina A Tejada1, Kris G Vargas2, Vicente Benites-Zapata3, Edward Mezones-Holguín4,5, Rafael Bolaños-Díaz1,6, Adrián V Hernandez5,7. 1. Unidad de Análisis y Generación de Evidencias en Salud Pública, Centro Nacional de Salud Pública, Instituto Nacional de Salud. Lima, Perú. 2. Department of Epidemiology, Erasmus MC. Rotterdam. Netherlands. 3. Centro de Investigación de Salud Pública, Instituto de Investigación, Facultad de Medicina Humana, Universidad de San Martín de Porres. Lima, Perú. 4. Intendencia de Investigación y Desarrollo, Superintendencia Nacional de Salud. Lima, Perú. 5. School of Medicine, Universidad Peruana de Ciencias Aplicadas. Lima, Perú. 6. Organización médica para el desarrollo de la salud. Lima, Perú. 7. Department of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic. Ohio, USA.
Abstract
OBJECTIVE: : To review evidence on the efficacy of HPV vaccines in the prevention of non-cancer lesions (anogenital warts [AGW], recurrent laryngeal papillomatosis and oral papillomatosis). MATERIALS AND METHODS: : We conducted a systematic review of randomized trials. We performed random effect models and effects were reported as relative risks (RR) and their confidence intervals (95%CI) following both intention to treat (ITT) and per protocol (PP) analyses. RESULTS: : We included six studies (n=27 078). One study was rated as high risk of bias. One study could not be included in the meta-analysis because it provided combined results. We found that quadrivalent vaccine reduced the risk of AGW by 62% (RR: 0.38, 95%CI:0.32-0.45, I2:0%) in the ITT analysis and by 95% (RR: 0.05, 95%CI:0.01-0.25, I2:66%) in the PP analysis. Subgroup analyses of studies in women or with low-risk of bias provided similar results. CONCLUSION: : HPV quadrivalent vaccine is efficacious in preventing AGW in men and women.
OBJECTIVE: : To review evidence on the efficacy of HPV vaccines in the prevention of non-cancer lesions (anogenital warts [AGW], recurrent laryngeal papillomatosis and oral papillomatosis). MATERIALS AND METHODS: : We conducted a systematic review of randomized trials. We performed random effect models and effects were reported as relative risks (RR) and their confidence intervals (95%CI) following both intention to treat (ITT) and per protocol (PP) analyses. RESULTS: : We included six studies (n=27 078). One study was rated as high risk of bias. One study could not be included in the meta-analysis because it provided combined results. We found that quadrivalent vaccine reduced the risk of AGW by 62% (RR: 0.38, 95%CI:0.32-0.45, I2:0%) in the ITT analysis and by 95% (RR: 0.05, 95%CI:0.01-0.25, I2:66%) in the PP analysis. Subgroup analyses of studies in women or with low-risk of bias provided similar results. CONCLUSION: : HPV quadrivalent vaccine is efficacious in preventing AGW in men and women.
Authors: Anita Lukács; Zsuzsanna Máté; Nelli Farkas; Alexandra Mikó; Judit Tenk; Péter Hegyi; Balázs Németh; László Márk Czumbel; Sadaeng Wuttapon; István Kiss; Zoltán Gyöngyi; Gábor Varga; Zoltán Rumbus; Andrea Szabó Journal: BMC Public Health Date: 2020-05-28 Impact factor: 3.295